Galapagos NV - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GLPG Nasdaq 2830 www.glpg.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galapagos NV

Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets - Apr 4th, 2026 6:16 am
Galapagos Partners With Gilead on Gamgertamig, Unlocks $500M Cash and Eyes 2027 Registrational Trials - Mar 31st, 2026 7:26 am
Gilead Expands Autoimmune Ambitions With Ouro Deal And Galapagos Collaboration - Mar 31st, 2026 2:16 am
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Mar 30th, 2026 11:30 pm
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline - Mar 26th, 2026 6:55 pm
Galapagos Announces Nomination of Gino Santini to its Board of Directors - Mar 26th, 2026 2:02 pm
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings - Mar 26th, 2026 2:01 pm
Sector Update: Health Care Stocks Advance Late Afternoon - Mar 24th, 2026 1:50 pm
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal - Mar 24th, 2026 1:03 pm
Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. - Mar 24th, 2026 12:00 pm
Gilead Sciences to Acquire Ouro Medicines in Up to $2.18 Billion Deal - Mar 24th, 2026 4:40 am
Gilead to buy Ouro Medicines for up to $2.2 billion - Mar 23rd, 2026 4:58 pm
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases - Mar 23rd, 2026 4:25 pm
Galapagos Receives Transparency Notification from Bank of America - Mar 17th, 2026 3:01 pm
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - Mar 10th, 2026 3:31 pm
Galapagos Receives Transparency Notifications from Bank of America - Mar 10th, 2026 3:01 pm
Assessing Galapagos (ENXTAM:GLPG) Valuation After Mixed Returns And A Modest Undervaluation Estimate - Mar 6th, 2026 11:07 pm
Galapagos Creates New Subscription Right Plan - Mar 6th, 2026 2:01 pm
Galapagos Appoints Tania Philipp as Chief Human Resources Officer - Mar 5th, 2026 2:01 pm
Galapagos NV (GLPG) Full Year 2025 Earnings Call Highlights: Strategic Shifts and Financial ... - Feb 24th, 2026 12:01 pm